Citigroup
AMAM

Citigroup’s Ambrx Biopharma Inc AMAM Stock Holding History

Citigroup’s Portfolio AMAM Stock Details AMAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-18,774
Closed -$267K – 5923
2023
Q4 		$267K Buy
+18,774
New +$213K ﹤0.01% 3795

Citigroup's AMAM Position: Q1 2024 in Review

Citigroup sold out of Ambrx Biopharma Inc (AMAM) in Q1 2024, closing a stake of 18,774 shares — an estimated $267K sold.

Citigroup first reported a position in AMAM in Q4 2023 and held it in 1 quarter. The position peaked at $267K in Q4 2023. 0 funds tracked by Wall St. Rank hold AMAM as of Q1 2024.

  • Citigroup reported no remaining Ambrx Biopharma Inc position as of Q1 2024 after selling out during the quarter.
  • Citigroup sold 18,774 Ambrx Biopharma Inc shares in Q1 2024, an estimated $267K.
  • Citigroup first reported a position in Ambrx Biopharma Inc in Q4 2023 and held it in 1 quarter.
  • Citigroup's Ambrx Biopharma Inc position peaked at $267K in Q4 2023.
  • 0 funds tracked by Wall St. Rank held Ambrx Biopharma Inc as of Q1 2024.

Based on Citigroup's 13F filing for Q1 2024, filed 10 May 2024.